Study of the clinical efficacy of the crystalline form of the immunomodulatory drug based on antimicrobial peptides and cytokines complex in the treatment of patients with inflammatory periodontal diseases

Abstract

On the basis of clinical periodontal indices of Muhlemann, RMA and Silness-Loe, the effectiveness of a new water-soluble form of the immunomodulatory drug Superlimf L in the treatment of inflammatory periodontal diseases was studied. Material and methods. 2 groups of patients with moderate periodontitis were formed: the experimental group (Group A) and the control group (Group B) (30 patients in each group). Before the start of treatment, all patients were taught the rules of correct brushing. Piezon-Master-400 and polishing the surfaces of the roots of the teeth in patients of the experimental group (A) were introduced into the periodontal pockets on cotton turundas with a solution of Superlimf® L. Previously, the pulvis of the Superlimf® L was dissolved in 5 ml of distilled water. Cotton turundas soaked in the preparation solution were introduced into periodontal pockets and soaked swabs were applied to the surfaces of gum — for 40 minutes. The procedures were carried out daily for 2 weeks. In the control group, the intervention was limited to the removal of dental deposits and subsequent controlled brushing of the teeth once every 3 days. The duration of the study was 2 weeks. An index assessment of the periodontal condition in patients of both groups was performed before treatment and, 3, 7 and 14 days after treatment. Treatment results. Clinically visible improvement in the condition of periodontal tissues after mechanical treatment occurred in patients of both groups after 3 days. The dynamics of the Silness-Loe index was very demonstrative in patients of both groups. Being initially almost equally high (2.35±0.45 units), after 3 days these values decreased by more than half. However, the difference in the decrease in the value of the Muhlemann index and PMA in patients of groups A and B was very significant. If in the control group (group B) after 3 days the intensity of bleeding during a probe test decreased by no more than 20%, then in patients in group A it decreased by almost half. In subsequent periods of observation, the decrease in inflammation and bleeding indices was also almost 3 times more intense in patients in group A than in patients in the control group. It is characteristic that the Silness-Loe plaque index already on the 7th day in patients in group B was significantly higher than in patients in group A. By the end of the study, both clinically and according to the index assessment of the condition of the periodontium in patients who received Superlimf® L, the condition of periodontal tissues was significantly better than in patients in the control group (Group B). Conclusion. Pronounced efficacy, the absence of adverse effects when using the product, good organoleptic indicators — all of the above allows specialists to use the powder form of the new drug Superlimf® L for the treatment of inflammatory periodontal diseases both in the conditions of dental units, as well as recommend to patients after their preliminary instruction and training apply the remedy at home.